$0.01
-0.00(-1.92%)
52W $0.01 – $0.59
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
$68.0KMkt Cap
$1MRev TTM
-$21MNI TTM
-0.0xP/E TTM
What Changed Recently
No significant events in the past 90 days.
Fundamentals
How The Business Makes Money
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Industry Biotechnology
Analyst View
Company Profile
CIK0001796129
ISINUS92731L3042
CUSIP92731L304
Phone650 800 6676
Address260 Sheridan Avenue, Palo Alto, CA, 94306, US
SEC EDGAR